APGE Announces Positive 52-Week Zumilokibart Data, 75% EASI-75, 86% vIGA 0/1, 6-Month Dosing, 2Q 2026 Phase 3 Readout, 2026 AAD Presentation
Apogee Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $79.30
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS